Expansion opportunities Amplity’s growth track with leadership change in 2026 and launches like In Practice indicate a momentum shift. This suggests potential for upsell or expansion within biopharma clients seeking more specialized medical communications and strategic platforms.

AI and digital enablement Recent product launches and technologies such as Ava (AI-powered chatbot) and AI-powered RWE posters at ISPOR highlight a commitment to digital, data-driven engagement. This openness to AI can be a doorway to data analytics, payer insights, and e-learning solutions for life sciences teams.

Global, full-service network Amplity positions as a global medical communications partner with full-service capabilities, journals, online resource centers, and thought-leader engagements. This creates cross-sell opportunities across medical education, publications, and stakeholder engagement for larger pharma accounts.

Leadership and credibility Recent CEO appointment and industry recognition such as Titan Award wins signal leadership credibility and market visibility. This can facilitate conversations with mid-to-large biopharma brands seeking proven partners with innovative branding and digital experiences.

Strategic events and partnerships Active participation in industry events (ISPOR 2026) and partnerships (BioSpace webinar) demonstrates alignment with current market needs like real-world evidence and biopharma talent strategies. This suggests opportunities to engage on RWE, clinical-to-commercial messaging, and talent-enabled communications programs.